The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal
Endocrine-Related Cancer · 17.04.2023 · 30 (8)
DOI: 10.1530/erc-23-0021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine-Related Cancer, erschienen am 17.04.2023. Verfasst von Chiara Villa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropathology, Hôpital Universitaire Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France. Hauptthemen laut MEDLINE: Pituitary Neoplasms, Neuroendocrine Tumors. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 67 Literaturangaben.
Abstract (Originalsprache)
The classification of tumours of the pituitary gland has recently been revised in the 2021 5th edition World Health Organization (WHO) Classification of Central Nervous System Tumours (CNS5) and 2022 5th edition WHO Classification of Endocrine and Neuroendocrine Tumours (ENDO5). This brief review aims to appraise the most relevant changes and updates introduced in the two classifications. A new nomenclature has been introduced in CNS5 and ENDO5 to align adenohypophyseal tumours with the classification framework of neuroendocrine neoplasia. The term pituitary neuroendocrine tumour (PitNET) with subtype information has therefore been adopted and preferred to adenoma. Pituitary carcinoma has been replaced by metastatic PitNET. The ICD-O coding has been changed from benign to malignant in line with NETs from other organs. Histological typing and subtyping based on immunohistochemistry for lineage-restricted pituitary transcription factors are regarded as the cornerstone for accurate classification. Such an approach does not fully reflect the complexity and dynamics of pituitary tumorigenesis and the variability of transcription factors expression. ENDO5 does not support a grading and/or staging system and argues that histological typing and subtyping are more robust than proliferation rate and invasiveness to stratify tumours with low or high risk of recurrence. However, the prognostic and predictive relevance of histotype is not fully validated. Recent studies suggest the existence of clinically relevant molecular subgroups and emphasize the need for a standardized, histo-molecular integrated approach to the diagnosis of PitNETs to further our understanding of their biology and overcome the unsolved issue of grading and/or staging system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuropathology, Hôpital Universitaire Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France.
- Inserm U1016, CNRS UMR 8104, Institut Cochin, Université Paris Descartes-Université de Paris, Paris, France.
- Department of Neurosurgery, Hôpital Universitaire Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France.
- Department of Endocrinology, Center for Rare Adrenal Diseases, Hôpital Cochin APHP, Paris, France.
- Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, "Groupement Hospitalier Est" Hospices Civils de Lyon, Bron, France.
- Lyon 1 University, Villeurbanne, France.
ORCID-Profile: Chiara Villa, Gerald Raverot
Zitieren
APA
Villa, C., Baussart, B., Assié, G., Raverot, G., & Roncaroli, F. (2023). The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal. Endocrine-Related Cancer, 30(8). https://doi.org/10.1530/erc-23-0021
Vancouver
Villa C, Baussart B, Assié G, Raverot G, Roncaroli F. The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal. Endocrine-Related Cancer. 2023;30(8). doi:10.1530/erc-23-0021
BibTeX
@article{Villa2023,
author = {Villa, Chiara and Baussart, Bertrand and Assié, Guillaume and Raverot, Gerald and Roncaroli, Federico},
title = {The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal},
journal = {Endocrine-Related Cancer},
year = {2023},
volume = {30},
number = {8},
doi = {10.1530/erc-23-0021}
}
EUVIMED